Tags

Type your tag names separated by a space and hit enter

Enhanced muscarinic receptor blockade with atropine in the asthmatic tracheobronchial tree. Evidence for increased drug delivery.
Am Rev Respir Dis. 1992 Apr; 145(4 Pt 1):756-61.AR

Abstract

We measured the competitive antagonistic effect of atropine in bronchi of 8 normal and 15 asthmatic subjects. Classic pharmacologic theory states that the degree of competitive antagonism depends only upon (1) antagonist concentration at the receptor and (2) receptor affinity. Delivery and affinity also influence agonist responsiveness, but measurement of bronchial antagonism allows study of these factors in isolation. Bronchial responsiveness to methacholine was measured as the cumulative dose required to produce a 35% fall in specific airway conductance (PD35). On different days three measurements of control PD35 were made on each subject. On 2 days PD35 was measured after inhalation of 0.14 mg atropine and, on another day, after intravenous injection of 0.32 mg atropine. The antagonist effect of atropine was measured as dose ratio - 1 (DR - 1), where DR = PD35 after atropine/control PD35. Geometric mean DR - 1 with inhaled atropine in asthmatic subjects (11.7) was 6.3 times that of normal subjects (1.9) (p less than 0.001), and DR - 1 with intravenous atropine in asthmatic subjects (8.0) was 5.6 times that of normal subjects (1.4) (p less than 0.001). In conclusion, there is enhanced muscarinic blockade from inhaled and intravenously administered atropine in asthmatic bronchi. We suggest that this is due to increased access of the drug to bronchial muscarinic receptors.

Authors+Show Affiliations

Department of Medicine, Charing Cross and Westminster Medical School, London, UK.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

1554197

Citation

Boskabady, M H., and P D. Snashall. "Enhanced Muscarinic Receptor Blockade With Atropine in the Asthmatic Tracheobronchial Tree. Evidence for Increased Drug Delivery." The American Review of Respiratory Disease, vol. 145, no. 4 Pt 1, 1992, pp. 756-61.
Boskabady MH, Snashall PD. Enhanced muscarinic receptor blockade with atropine in the asthmatic tracheobronchial tree. Evidence for increased drug delivery. Am Rev Respir Dis. 1992;145(4 Pt 1):756-61.
Boskabady, M. H., & Snashall, P. D. (1992). Enhanced muscarinic receptor blockade with atropine in the asthmatic tracheobronchial tree. Evidence for increased drug delivery. The American Review of Respiratory Disease, 145(4 Pt 1), 756-61.
Boskabady MH, Snashall PD. Enhanced Muscarinic Receptor Blockade With Atropine in the Asthmatic Tracheobronchial Tree. Evidence for Increased Drug Delivery. Am Rev Respir Dis. 1992;145(4 Pt 1):756-61. PubMed PMID: 1554197.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Enhanced muscarinic receptor blockade with atropine in the asthmatic tracheobronchial tree. Evidence for increased drug delivery. AU - Boskabady,M H, AU - Snashall,P D, PY - 1992/4/1/pubmed PY - 1992/4/1/medline PY - 1992/4/1/entrez SP - 756 EP - 61 JF - The American review of respiratory disease JO - Am Rev Respir Dis VL - 145 IS - 4 Pt 1 N2 - We measured the competitive antagonistic effect of atropine in bronchi of 8 normal and 15 asthmatic subjects. Classic pharmacologic theory states that the degree of competitive antagonism depends only upon (1) antagonist concentration at the receptor and (2) receptor affinity. Delivery and affinity also influence agonist responsiveness, but measurement of bronchial antagonism allows study of these factors in isolation. Bronchial responsiveness to methacholine was measured as the cumulative dose required to produce a 35% fall in specific airway conductance (PD35). On different days three measurements of control PD35 were made on each subject. On 2 days PD35 was measured after inhalation of 0.14 mg atropine and, on another day, after intravenous injection of 0.32 mg atropine. The antagonist effect of atropine was measured as dose ratio - 1 (DR - 1), where DR = PD35 after atropine/control PD35. Geometric mean DR - 1 with inhaled atropine in asthmatic subjects (11.7) was 6.3 times that of normal subjects (1.9) (p less than 0.001), and DR - 1 with intravenous atropine in asthmatic subjects (8.0) was 5.6 times that of normal subjects (1.4) (p less than 0.001). In conclusion, there is enhanced muscarinic blockade from inhaled and intravenously administered atropine in asthmatic bronchi. We suggest that this is due to increased access of the drug to bronchial muscarinic receptors. SN - 0003-0805 UR - https://www.unboundmedicine.com/medline/citation/1554197/Enhanced_muscarinic_receptor_blockade_with_atropine_in_the_asthmatic_tracheobronchial_tree__Evidence_for_increased_drug_delivery_ L2 - https://www.atsjournals.org/doi/10.1164/ajrccm/145.4_Pt_1.756?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -